Here's what energy transition companies stood out to Rice Alliance's experts. Photo via Rice Alliance

At the 20th annual Energy Tech Venture Forum presented by Rice Alliance for technology and Entrepreneurship, 11 startups scored recognition from the event's investors who evaluated over 90 early-stage energy transition companies.

"The selection process was both exhilarating and challenging given the incredible ideas we've seen today," says Jason Sidhu, director of information services business engagement at TC Energy, who announced the top companies. "I want to extend my gratitude to every company that participate din this year's Energy Tech Venture Forum. Your commitment to solving energy problems and pursuing ambitions ideas is truly commendable."

In addition to the top 10 most-promising companies, the event's attendees decided the people's choice pick out of the 50 or so pitching companies. The winner of that recognition was Calgary, Alberta-based Galatea Technologies, which has created a tech platform to enhance workflows for operational, financial, and environmental performance.

The top companies, according to the Rice Alliance experts and investors, were:

  • Circular economy startup, Polystyvert. Based in Montreal, the company has created a unique dissolution recycling process that creates a material that can contribute to cutting carbon emissions by up to 90 percent.
  • United Kingdom-based Mirico provides a tracking technology to its customers to measure climate gases (like methane, carbon dioxide, nitrous oxide, and ammonia), across areas up to half a square mile and in all conditions.
  • Protein Evolution, from New Haven, Connecticut, taps into a combination of green chemistry and enzyme technology to break down synthetic polymers.
  • Another Canadian company, Ayrton Energy, based in Calgary, created a liquid organic H2 carrier (LOHC) storage technology presents an opportunity for large, scalable and efficient transport of H2 over long distances.
  • Also representing New Haven, Connecticut, Carbon Loop is on a mission to make carbon capture and conversion scalable through carbon dioxide electrolysis using a proprietary catalyst to convert captured carbon dioxide into methanol.d
  • Based in London, Mobilus Labs has designed a new way for frontline communication with an in-helmet hardware and software solution. software solution designed for the frontline workforce.
  • 1s1 Energy, based in California, is working on producing low-cost green hydrogen by creating new materials to unlock unprecedented electrolyzer efficiency, durability, and more.
  • From Skokie, Illinois, Numat is specializing in solutions within Metal-organic framework (MOF) research to enhance the process of separating the hazardous chemicals negatively impacting human health and the environment.
  • Mantel, headquartered in Cambridge, Massachusetts, created a molten borate technology to capture CO2 in a new and efficient way.
  • The lone Houston-based company, Mars Materials is working to produce acrylonitrile using CO2 and biomass to enable decarbonization applications in carbon fiber and wastewater treatment.
------

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”